Search
Entrada Therapeutics Inc
TRDAAdd to Watchlist
7.570USD
-0.030-0.39%
Close 08-21 16:00（ET）
295.53MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-21The current earnings forecast score of Entrada Therapeutics Inc is 8.50, ranking 107 out of 377 in the Biotechnology & Medical Research industry. The average price target is 16.50, with a high of 20.00 and a low of 13.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
16.648
Target Price
+129.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Entrada Therapeutics Inc
TRDA
8
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Entrada Therapeutics Inc's expected revenue for the next quarter?
Entrada Therapeutics Inc's expected revenue is 5.26M.
What is Entrada Therapeutics Inc's price target?
Analysts forecast that Entrada Therapeutics Inc's price target is USD 16.50, with the highest forecast at USD 20.00 and the lowest forecast at USD 13.00.
How have Entrada Therapeutics IncTRDA's recent earnings per share performed?
The market expectation was USD -1.01, while Entrada Therapeutics IncTRDA's earnings per share (EPS) for the previous quarter was USD -0.95. EPS for the next quarter is expected at USD -1.01.
What is the analyst rating for Entrada Therapeutics Inc?
Based on the ratings of Entrada Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.